BASF (XTRA:BAS) Launches SkinNexus Collag3n, Is The Recent Pullback Leaving Value On The Table?
BASF (XTRA:BAS) is back in focus after launching SkinNexus Collag3n, a 100% human-identical recombinant Collagen III fragment for the personal care market, developed with Bota Biosciences and premiered at in-cosmetics Global 2026.
See our latest analysis for BASF.
Despite the excitement around SkinNexus Collag3n and recent decisions to redeem outstanding notes early, BASF’s 30-day share price return is down 3.94% and the 90-day share price return is down 12.99%. At the same time, the 1-year total shareholder return of 14.44% and 3-year total shareholder return of 23.39% point to momentum that has been building over a longer horizon.
If this kind of specialty chemicals story has your attention, it can be worth broadening your search with a curated list of 105 top founder-led companies
After a strong 1-year and 3-year run, followed by a weaker recent stretch, BASF sits at an interesting crossroads. Is more of the potential already reflected in the share price, or does the current valuation still leave meaningful upside on the table?
Most Popular Narrative: 9.5% Undervalued
The most followed narrative currently places BASF’s fair value at €52.55, compared with the recent close at €47.55, framing the recent pullback in a different light.
Significant cost-savings programs (targeting €2.1 billion annual savings by end of 2026), alongside the completion of the major China Verbund investment (with project costs under budget and CapEx falling below depreciation from 2026), will meaningfully improve operating leverage and free cash flow, with cost competitiveness directly supporting improved net margins.
Want to see what really underpins that fair value for BASF? The narrative leans on a careful mix of revenue growth, margin expansion, and a reset profit multiple. The exact combination may surprise you.
Result: Fair Value of €52.55 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, BASF’s story could change quickly if European demand stays weak or if overcapacity in global base chemicals keeps margins under pressure for longer than expected.
Find out about the key risks to this BASF narrative.
Another View: What BASF’s P/E Is Telling You
There is a very different picture when you look at BASF through its current P/E. At 27.1x, the stock trades richer than the European chemicals industry at 19x and above a fair ratio of 25.9x. That premium suggests less margin for error if the story wobbles from here.
Before leaning too heavily on any one approach, it can help to see how this valuation gap fits into the broader numbers narrative for BASF, including earnings quality, balance sheet strength and peer comparison, in our valuation breakdown: See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed messages so far on BASF? Take a closer look at the numbers, consider the 3 key rewards and 2 important warning signs, and decide how comfortable you are with the balance of risk and opportunity by checking the 3 key rewards and 2 important warning signs
Looking for more investment ideas beyond BASF?
If you like the kind of detail behind BASF’s story, do not stop here, fresh opportunities often show up first in broader idea lists, not headlines.
- Target long term compounding potential by scanning a curated set of 212 high quality undervalued stocks that combine solid fundamentals with prices implying a possible discount.
- Strengthen your income stream by reviewing 472 dividend fortresses that focus on higher-yield payouts supported by underlying business metrics.
- Protect your downside by filtering for resilience with the 297 resilient stocks with low risk scores that screen for companies with lower overall risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com